Published in J Natl Cancer Inst on October 04, 2000
Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A (1983) 5.00
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res (1998) 3.39
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res (1995) 3.20
Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med (1983) 3.04
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res (2000) 2.96
The rapid induction by phytohemagglutinin of increased alpha-aminoisobutyric acid uptake by lymphocytes. J Clin Invest (1971) 2.94
Sleep and behavior problems in school-aged children. Pediatrics (2001) 2.23
Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ (1996) 2.18
Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res (1984) 2.17
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol (2000) 2.13
Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem (1998) 2.06
Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res (1993) 2.03
Blockage of EGF receptor signal transduction causes reversible arrest of normal and immortal human mammary epithelial cells with synchronous reentry into the cell cycle. Exp Cell Res (1993) 1.84
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol (1999) 1.82
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res (2000) 1.82
Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A (1986) 1.72
Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res (1993) 1.70
Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem (1994) 1.69
The role of monocytes in human lymphocyte activation by mitogens. J Immunol (1979) 1.67
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res (1999) 1.66
Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst (1997) 1.63
Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest (1995) 1.61
Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res (1986) 1.60
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst (1993) 1.56
Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J Biol Chem (1984) 1.55
Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res (1996) 1.54
Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J Biol Chem (1991) 1.48
Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem (1998) 1.48
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res (2001) 1.37
Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol Cell Biol (1991) 1.32
Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer (2000) 1.31
Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene (1999) 1.31
Adenosine metabolism in phytohemagglutinin-stimulated human lymphocytes. J Clin Invest (1976) 1.29
Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J Biol Chem (2000) 1.29
RNA in nascent DNA from cultured human lymphocytes. Nat New Biol (1973) 1.28
Inhibition of human natural cytotoxicity by macromolecular antiproteases. J Immunol (1981) 1.27
Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J Cell Biol (1995) 1.23
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res (1997) 1.23
Epidermal growth factor-induced growth inhibition requires Stat1 activation. Cell Growth Differ (1998) 1.22
Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene (1999) 1.21
Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. J Biol Chem (2000) 1.18
Enhanced effects of prostaglandin E1 and dibutyryl cyclic AMP upon human lymphocytes in the presence of cortisol. J Clin Invest (1973) 1.18
The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol (1996) 1.14
Separation of isolated Chinese hamster metaphase chromosomes into three size-groups. J Mol Biol (1968) 1.14
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst (1996) 1.13
Consumption of EGF by A431 cells: evidence for receptor recycling. J Cell Biol (1993) 1.13
Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci U S A (1996) 1.11
Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene (1996) 1.11
Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother (1993) 1.10
Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst (1987) 1.08
Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene (2001) 1.08
Ribonucleotides in closed circular mitochondrial DNA from HeLa cells. Biochem Biophys Res Commun (1973) 1.07
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res (1995) 1.06
9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res (1994) 1.06
Ceramide stimulates epidermal growth factor receptor phosphorylation in A431 human epidermoid carcinoma cells. Evidence that ceramide may mediate sphingosine action. J Biol Chem (1991) 1.05
Autocrine regulation of membrane transforming growth factor-alpha cleavage. J Biol Chem (1996) 1.03
DNA synthesis and proliferation of human lymphocytes in vitro. I. Cell kinetics of response to phytohemagglutinin. J Immunol (1978) 1.03
Requirement for monocytes in the spontaneous cytotoxic effects of human lymphocytes against non-lymphoid target cells. Nature (1980) 1.02
Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res (2000) 1.02
Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst (1997) 1.01
Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis (1995) 1.00
Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst (1989) 1.00
The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat (1994) 1.00
Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol (1989) 0.99
Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res (1991) 0.98
Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res (1986) 0.98
Inhibition of human lymphocyte stimulation by steroid hormones: cytokinetic mechanisms. Clin Exp Immunol (1977) 0.98
Effects of epidermal growth factor receptor concentration on tumorigenicity of A431 cells in nude mice. Cancer Res (1986) 0.97
Autonomous proliferation of colon cancer cells that coexpress transforming growth factor alpha and its receptor. Variable effects of receptor-blocking antibody. Gastroenterology (1992) 0.96
The circulating "atypical" lymphocyte. Hum Pathol (1978) 0.96
Inhibition of human lymphocyte proliferation by monoclonal antibody to transferrin receptor. Blood (1983) 0.95
Regulation of TGF-alpha expression in human keratinocytes: PKC-dependent and -independent pathways. J Cell Physiol (1992) 0.95
Drug-induced agranulocytosis: in vitro evidence for immune suppression of granulopoiesis and a cross-reacting lymphocyte antibody. Blood (1979) 0.94
Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells. Endocrinology (1990) 0.94
Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene (1998) 0.94
Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor. Breast Cancer Res Treat (1999) 0.94
Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. Cancer Res (1992) 0.93
EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer (1995) 0.93
Therapeutic application of anti-growth factor receptor antibodies. Curr Opin Oncol (1998) 0.93
Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res (1997) 0.93
Role of transferrin, Fe, and transferrin receptors in myeloid leukemia cell growth. Studies with an antitransferrin receptor monoclonal antibody. J Clin Invest (1985) 0.93
Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther (1994) 0.92
Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res (1999) 0.92
Isolation and characterization of human metaphase chromosomes. Proc Natl Acad Sci U S A (1966) 0.92
The carbohydrate specificities of the monoclonal antibodies 29.1, 455 and 3C1B12 to the epidermal growth factor receptor of A431 cells. Biosci Rep (1985) 0.90
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer (2001) 0.89
Mitogenic action of tumor necrosis factor in human fibroblasts: interaction with epidermal growth factor and platelet-derived growth factor. J Cell Physiol (1988) 0.88
Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies. J Biol Chem (1993) 0.88
Growth regulation of A431 cells. Modulation of expression of transforming growth factor-alpha mRNA and 2',5'-oligoadenylate synthetase activity. J Biol Chem (1990) 0.88
Characterization of normal peripheral blood lymphocyte colony-forming cells: cell cycle status, surface markers, and cellular growth requirements. Blood (1983) 0.88
Control of transcription of RNA rich in polyadenylic acid in human lymphocytes. Proc Natl Acad Sci U S A (1972) 0.87
Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res (1989) 0.86
The role of target cells, monocytes, and Fc receptor-bearing lymphocytes in human spontaneous cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol (1980) 0.86
Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. Immunol Lett (1993) 0.86
Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res (1986) 0.86
Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells. J Cell Physiol (1995) 0.86
Adenylate cyclase in thymus-derived and bone marrow-derived lymphocytes from normal donors and patients with chronic lymphocytic leukemia. J Clin Invest (1979) 0.86